Novartis properly warned of Zometa's risks, jury decides

Novartis ($NVS) prevailed in the latest court battle over jawbone injuries in Zometa patients. The company did properly warn patients about the drug's risks, a New Jersey jury determined after a 13-day trial.

The jury voted 7-1 in Novartis' favor, in a case pitting plaintiff and Zometa user Beverly Meng against the Swiss drugmaker. It was the second Zometa case to go to trial in state court and one of many consolidated in the New Jersey court.

Novartis has been fighting hundreds of claims of osteonecrosis of the jaw in patients who used the bisphosphonate treatment for osteoporosis. The entire class of drugs has carried FDA warnings about the risk of jawbone death since 2005. The agency has considered placing limits on use of the bone treatments, particularly on long-term treatment, but so far hasn't done so.

Zometa has already reached the end of its patent life; it lost exclusivity in March. Novartis had tried to develop it for breast cancer treatment but pulled its FDA application for that use in 2010. The new indication would have given the company another three years of Zometa exclusivity. The company brought in more than $1 billion in sales last year.

- read the news at Law 360 (sub. req.)

Special Report: Zometa - Top 15 drug patent losses for 2013

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.